Economic Overview - In Q2, the actual GDP growth was 5.2% year-on-year, while nominal GDP growth fell to 3.9%, marking a decline of 0.2 and 0.7 percentage points from Q1 respectively[4] - The nominal GDP growth rate has dropped below 4%, the lowest in nearly three years, primarily due to strong supply and weak demand characteristics[23] Supply and Demand Balance - Q3 is expected to see a balance between supply and demand, driven by the implementation of "anti-involution" policies and improved confidence in the real sector[2] - The recovery in consumption is gradually being confirmed, with "anti-involution" policies likely being a key factor influencing Q3 economic performance[4] Investment Trends - Fixed asset investment in Q2 grew by only 1.8% year-on-year, a significant drop of 2.4 percentage points from Q1, with infrastructure and manufacturing investments experiencing widespread contraction[11] - In June, fixed asset investment saw a month-on-month decline of 0.1%, marking a historical low[11] Consumer Behavior - The nominal growth rate of social retail sales in Q2 was 4.5%, slightly down by 0.1 percentage points from Q1, indicating a moderate increase in consumer spending[19] - In June, social retail sales growth fell to 4.8%, a significant drop of 1.6 percentage points from the previous month, with most categories experiencing a broad decline[20] Inflation and Market Dynamics - The report suggests that moderate inflation positively impacts corporate operations and household balance sheets, with expectations of a gradual recovery in nominal GDP growth[2] - The bond market is currently benefiting from a low inflation environment and ample liquidity, although the upward potential for bond prices is limited in the short term[27] Geopolitical and Policy Risks - Risks include geopolitical tensions and the potential for policy changes that exceed expectations, which could impact economic stability[3]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 29.82 CNY, compared to the current stock price of 24.49 CNY as of July 18, 2025 [4]. Core Insights - The company has made significant advancements in AI technology, particularly with its "Steel Big Model," which has been recognized in the SAIL Awards TOP30, affirming its leadership in the digital transformation of the steel industry [1]. - The successful production of the "1550 Acid Washing and Rolling Mill Unit" at the Guangxi Hongwang project marks a critical milestone, showcasing the application of the company's domestic large PLC control systems and setting a new benchmark for high-end metallurgical equipment [1][3]. - The company is actively integrating AI into the steel industry, developing a comprehensive "AI + Steel" solution that combines platform, data, computing power, models, and scenarios, and has initiated over 100 "AI+" application instances [2]. Financial Performance and Projections - The company is projected to achieve revenues of 143.13 billion CNY, 154.81 billion CNY, and 163.92 billion CNY for the years 2025, 2026, and 2027 respectively, with net profits expected to be 24.57 billion CNY, 28.41 billion CNY, and 30.72 billion CNY during the same period [7]. - The revenue growth rate is expected to be 4.9% in 2025, 8.2% in 2026, and 5.9% in 2027, while net profit growth rates are projected at 8.5%, 15.6%, and 8.1% respectively [9][10]. - The company’s earnings per share (EPS) is expected to increase from 0.85 CNY in 2025 to 1.07 CNY in 2027, reflecting a positive growth trajectory [10]. Market Position and Competitive Advantage - The company is positioned as a leader in the domestic large PLC market, with its products being integral to the operational efficiency of key production lines, such as the Guangxi Hongwang project, which has a designed annual capacity of 1.5 million tons and a maximum operating speed of 1580 m/min [3]. - The company is also focusing on the development of humanoid robots integrated with AI for industrial applications, aiming to establish a robust ecosystem in the steel and related industries [2].

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a 6-month target price of 95.60 CNY per share, based on an expected EPS of 4.78 CNY for 2025 and a PE ratio of 20 times [4][9]. Core Insights - The company is evolving into a leading integrated CRDMO service platform, driving continuous growth in its business segments, particularly in small molecule D&M, TIDES, testing, and biological services [13][15]. - The CRDMO industry is expected to see a gradual recovery in outsourcing demand, driven by ongoing investments in drug development, particularly in GLP-1 and ADC sectors [27][28]. - The company has shown robust growth in its project pipeline, with significant increases in both the number of projects and commercialized products, indicating strong operational capabilities and market demand [40][42]. Summary by Sections 1. Integrated CRDMO Service Platform - The company has developed into a global leader in integrated CRDMO services, expanding its global network and service offerings since its establishment in 2000 [13][14]. - Revenue has grown from 4.883 billion CNY in 2015 to an expected 39.241 billion CNY in 2024, with a CAGR of 26.05%, while net profit has increased from 0.349 billion CNY to 9.450 billion CNY in the same period, reflecting a CAGR of 44.27% [15][19]. 2. CRDMO Industry Outlook - The report anticipates a recovery in CRDMO outsourcing demand, supported by the rapid commercialization of drugs like GLP-1 and ADC, which are expected to drive revenue growth for CRDMO companies [27][28]. - The company’s backlog of orders reached 523.3 billion CNY by March 2025, representing a year-on-year increase of 47.1% [35]. 3. Business Segment Performance 3.1. Chemical Business - The small molecule D&M business is experiencing steady growth, with revenue reaching 17.870 billion CNY in 2024, and a projected increase of 13.8% year-on-year in Q1 2025 [40][42]. - The TIDES business is benefiting from high demand in the peptide sector, with revenue expected to grow from 2.04 billion CNY in 2022 to 5.8 billion CNY in 2024, reflecting a CAGR of 68.74% [54][55]. 3.2. Testing Business - The testing segment, including SMO services, has maintained a leading position in the industry, with revenue from clinical CRO and SMO services growing from 1.087 billion CNY in 2020 to 1.810 billion CNY in 2024 [59][61]. - The SMO service team has expanded to 4,700 personnel, covering over 1,000 hospitals across 150 cities, contributing to the successful approval of 255 new products over the past decade [61][62]. 3.3. Biological Business - The company is focusing on building capabilities related to new molecular types, with over 290 clients served and more than 1,400 projects delivered since 2021 in the nucleic acid platform [63][64]. - The revenue from new molecular types is increasingly contributing to the overall growth of the biological segment [63].

Group 1 - The report highlights that the current market structure favors low-valuation large-cap growth stocks, particularly represented by the ChiNext Index, which is expected to continue outperforming in the third quarter of this year [2][5][60] - The ChiNext Index currently has a PE ratio of 33.89, placing it in the 23.82% percentile over the past decade, indicating a relative valuation advantage compared to other major indices [2][67] - The report notes that the banking sector has significantly contributed to the overall market performance, with the Shanghai Composite Index rising from 3347 points at the beginning of the year to around 3534 points, largely driven by strong bank performance [1][33] Group 2 - The report discusses the historical divergence in returns between the bank-microcap "barbell strategy" and mid-cap growth assets, indicating that the current divergence is at historical extremes [3][62] - It emphasizes that the banking sector's dividend yield remains attractive, but the relative appeal has diminished as the yield compared to long-term bond rates has decreased to its lowest level since April 2021 [3][40] - The report suggests that the ongoing "supply-side reform" and the emergence of new economic drivers such as AI, innovative pharmaceuticals, and new energy vehicles are creating favorable conditions for mid-cap growth stocks to regain their performance [3][60][73] Group 3 - The report indicates that the current market environment is characterized by a strong liquidity backdrop, which is expected to benefit large-cap growth stocks as funds flow from banks to non-banking sectors and eventually to technology and undervalued large-cap growth stocks [4][51] - It highlights that the recent changes in quantitative trading regulations are likely to impact high-frequency trading strategies, potentially leading to a more stable market environment in the long term [21][27] - The report notes that the active equity funds have shown strong performance this year, significantly outperforming the broader market indices, indicating a shift in investor sentiment towards growth-oriented sectors [59][60]

Investment Rating - The report maintains a "Buy-A" rating for the company [6] Core Views - The company is expected to achieve a revenue of 923 billion yuan in the first half of 2025, representing a year-on-year increase of 1.03%, while the net profit attributable to shareholders is projected to be 63.4 billion yuan, down 10.2% year-on-year [1] - The second quarter of 2025 saw a revenue of 523.5 billion yuan, an increase of 7.8% year-on-year and 30.8% quarter-on-quarter, driven by new vehicle launches and improved overseas sales [2] - The company is entering a new growth phase with the launch of new models and a focus on direct-to-consumer channels, which is expected to enhance brand value and sales [4] Summary by Sections Financial Performance - In Q2 2025, the company achieved a net profit of 45.9 billion yuan, up 19.1% year-on-year and 161.9% quarter-on-quarter, while the non-recurring net profit was 21.1 billion yuan, down 30.1% year-on-year [3] - The average selling price (ASP) per vehicle in Q2 2025 reached 167,000 yuan, a decrease of 2.1% year-on-year but an increase of 7.3% quarter-on-quarter [2] Market Outlook - The mainstream market for new vehicles is expected to see an upward sales trend, supported by the successful launch of new models and a comprehensive marketing strategy [4] - The company has significant potential in the off-road vehicle market, with the Hi4Z technology expected to enhance product offerings and profitability [4] - The company has a diverse product range and strong technological capabilities, indicating substantial export potential as new models and powertrains are introduced [4] Valuation and Projections - The report forecasts net profits for 2025, 2026, and 2027 to be 140.3 billion yuan, 174.0 billion yuan, and 209.6 billion yuan respectively, with corresponding price-to-earnings ratios of 13.4, 10.8, and 9.0 times [4][10] - The six-month target price is set at 32.79 yuan per share, reflecting a 20 times price-to-earnings ratio for 2025 [4]

Investment Rating - The report maintains an investment rating of "Leading the Market - A" for the real estate sector [7]. Core Viewpoints - The central urban work conference emphasized the need to steadily advance the transformation of urban villages and dilapidated housing, shifting the focus from large-scale expansion to improving existing stock [1]. - The report suggests that the current push for urban village transformation aims to enhance the quality and efficiency of existing projects rather than generating new demand, indicating a more cautious approach compared to previous years [1]. - The report recommends focusing on companies that are likely to reverse their current difficulties, such as China Vanke and New Town Holdings, as well as leading firms maintaining land acquisition intensity like China Merchants Shekou, Greentown China, Poly Developments, and Binjiang Group [1]. Sales Review (July 12-18) - A total of 11,000 units were sold across 32 monitored cities, representing a week-on-week decrease of 4.8%. Cumulatively, 452,000 units have been sold in 2025, down 5.9% year-on-year [2][13]. - In first-tier cities, 3,875 units were sold, up 28.2% week-on-week, with a cumulative total of 130,000 units sold in 2025, reflecting a year-on-year increase of 5.3% [2][14]. - Second-tier cities saw sales of 5,743 units, down 20.4% week-on-week, with a cumulative total of 270,000 units sold in 2025, down 10.4% year-on-year [2][14]. - Third-tier cities recorded 1,351 units sold, up 5% week-on-week, with a cumulative total of 52,000 units sold in 2025, down 6.5% year-on-year [2][14]. Land Supply (July 7-13) - The planned construction area for residential land supply across 100 cities was 3.82 million square meters, with a cumulative supply of 11,756 million square meters in 2025, down 12.1% year-on-year [3][22]. - The average floor price for land supply across 100 cities was 4,293 yuan per square meter, with a recent four-week average of 4,846 yuan per square meter, reflecting a week-on-week decrease of 1.7% and a year-on-year decrease of 4.3% [3][24]. Land Transactions (July 7-13) - The planned construction area for residential land transactions across 100 cities was 2.5 million square meters, with a cumulative total of 10,272 million square meters sold in 2025, up 6.9% year-on-year [4][46]. - The average transaction floor price for residential land across 100 cities was 5,933 yuan per square meter, reflecting a week-on-week increase of 4% and a year-on-year decrease of 27.7% [4][48].

Investment Rating - The report maintains an "Outperform" rating for the environmental and public utility sector [7]. Core Insights - The report emphasizes the potential of Real World Assets (RWA) in conjunction with renewable energy companies, highlighting that RWA could become a significant development direction for stablecoins, with a projected market size of $16 trillion by 2030 [24][39]. - The report discusses the recent advancements in RWA, particularly in Hong Kong, where the Ensemble project has initiated themes related to green and sustainable finance, indicating a shift towards tokenizing assets like carbon credits and renewable energy charging stations [39][40]. Summary by Sections 1. RWA and Renewable Energy - RWA connects real-world assets with digital finance, providing unique value in bridging virtual and real economies [27]. - The Ensemble project in Hong Kong includes green finance as a key theme, with the first project involving the tokenization of electric vehicle charging stations [39][40]. - RWA technology can lower investment thresholds and attract more investors, offering new financing channels for renewable energy companies [42]. 2. Market Review - From July 5 to July 18, the Shanghai Composite Index rose by 1.79%, while the environmental index increased by 2.66%, outperforming the composite index [43]. - The public utility index decreased by 0.27%, underperforming the Shanghai Composite Index by 2.06 percentage points [43]. 3. Market Information Tracking - In July 2025, the average transaction price for electricity in Jiangsu was 395.6 RMB/MWh, up 26.47% month-on-month [55]. - The price of thermal coal at Qinhuangdao Port was reported at 642 RMB/ton, reflecting a 19 RMB/ton increase from the previous week [58]. 4. Industry Dynamics - The report notes that the garbage incineration sector is seeing improved cash flow due to debt reduction policies, while companies are exploring new trends such as high-energy direct power supply [13]. - The water service sector is expected to enhance profitability as residential water prices gradually adjust [13]. 5. Investment Portfolio and Recommendations - For public utilities, the report suggests focusing on thermal power companies that are expected to perform well due to proximity to coal production areas and cost reductions [12]. - In the green energy sector, companies that integrate power generation, sales, and consumption are recommended for their resilience against market disruptions [12].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the electronics industry [6]. Core Insights - The electronics industry is experiencing significant growth driven by substantial investments in AI data centers and advanced semiconductor processes. Companies like Meta are investing "hundreds of billions" in AI infrastructure, while TSMC and ASML report strong quarterly earnings, indicating robust demand for advanced chips [1][4][2]. - The semiconductor sector is highlighted as a key area for investment, with companies like Nvidia and AMD resuming sales of AI chips to China, which could lead to substantial revenue recovery [2][12]. - The report emphasizes the performance of specific companies within the electronics sector, noting significant profit increases for firms like Pengding Holdings and Shengyi Technology, driven by product optimization and high-value product ratios [1][4]. Summary by Sections Industry Performance - The electronics sector saw a weekly increase of 2.15%, ranking 7th among all industries [5][11]. - The semiconductor sub-sector has a PE ratio of 83.52, indicating a high valuation compared to historical averages [41]. Company Highlights - ASML reported a Q2 net sales of €7.7 billion with a gross margin of 53.7%, and TSMC achieved revenues of $30.07 billion, a 44.4% year-on-year increase [3][4]. - Pengding Holdings forecasted a net profit of 1.2-1.26 billion yuan for the first half of the year, reflecting a year-on-year increase of 52.79%-60.20% [1]. Market Trends - The report notes that the semiconductor investment share in total wafer fab investments is increasing, particularly in the DRAM sector, which is performing strongly [3]. - The demand for RISC-V chips is expected to lead the market, with significant growth projected in consumer electronics [24]. Future Outlook - The report suggests focusing on companies within the computing power supply chain, including Shenghong Technology, Huadian Technology, and others, as potential investment opportunities [12].

Investment Rating - The report maintains an investment rating of "Outperform" [6] Core Insights - The report highlights that Weili Zhibo is set to officially list on the Hong Kong Stock Exchange on July 25, 2025, with a pipeline of approximately 14 candidate drugs, 6 of which are in clinical development. The core product, the second-generation IO product PD-L1/4-1BB bispecific antibody LBL-024, is currently in a key registration clinical phase for treating lung neuroendocrine tumors [2][18] - The report notes that several PD-L1/4-1BB bispecific antibodies are under development globally, with Genmab's Acasunlimab leading in progress, having initiated a Phase III clinical trial for PD-L1 positive NSCLC in the second line. Weili Zhibo's LBL-024 is also in a critical registration clinical study for lung neuroendocrine tumors [21][22] - Early data from the PD-L1/4-1BB bispecific antibodies indicate that Weili Zhibo's LBL-024 has shown excellent overall response rate (ORR) data in first-line SCLC treatment, while Genmab's Acasunlimab has demonstrated superior survival data in second-line PD-L1 positive NSCLC [26] Summary by Sections Weekly New Drug Market Review - From July 14 to July 20, 2025, the top five companies in the new drug sector by stock price increase were Lepu Biotech (62.0%), Deqi Pharma (47.04%), Kaituo Pharma (41.99%), JAKS (41.95%), and Gilead Sciences (31.15%) [14][16] Weekly New Drug Industry Key Analysis - Weili Zhibo's innovative drug pipeline includes 14 candidate drugs, with 6 in clinical development. The focus is on the PD-L1/4-1BB bispecific antibody LBL-024, which is in a key registration clinical phase for lung neuroendocrine tumors [2][18] Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were granted this week, but 6 new drug applications were accepted [3] Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 35 new drug clinical applications were approved, and 28 new drug clinical applications were accepted [4] Domestic Market Key Events TOP3 - Baiyue Shenzhou's application for the injection of Talazotuzumab for treating extensive-stage small cell lung cancer (ES-SCLC) has been accepted [5] Overseas Market Key Events TOP3 - Otsuka Pharmaceutical's APRIL antibody is expected to be included in priority review for treating adult primary immunoglobulin A nephropathy [10]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 41.50 CNY, compared to the current stock price of 33.86 CNY as of July 18, 2025 [6]. Core Insights - The company is expected to benefit significantly from the digital transformation and high growth trends in the energy sector, particularly in the development of new power systems. Projected revenues for 2025, 2026, and 2027 are 40.45 billion CNY, 53.92 billion CNY, and 72.09 billion CNY respectively, with net profits of 4.69 billion CNY, 5.94 billion CNY, and 7.99 billion CNY [12][14]. Summary by Sections Recent Developments - The company successfully completed a black start test for a 100MWh grid-type energy storage system in Yunnan, marking a significant milestone as the first of its kind in the southern power grid region [2][3]. - The company has developed a comprehensive intellectual property system based on its self-developed "machine replaces human" technology, which has generated direct economic benefits of 639 million CNY over the past three years [2]. Business Expansion - The company is advancing its power special robots and drones business, which are crucial for intelligent inspection and operations in the power grid. The introduction of various inspection robots and drones aims to enhance operational efficiency and expand applications in multiple sectors [4]. Financial Performance - The company reported a total market value of approximately 19.12 billion CNY and a circulating market value of about 7.73 billion CNY [6]. - The projected net profit margin for the upcoming years is expected to remain stable, with a net profit margin of 11.1% in 2023, slightly increasing to 11.6% in 2025 [14].